ProCE Banner Activity

Phase III EV-302/KEYNOTE-A39: Subgroup Analyses of EV + Pembrolizumab vs Chemotherapy in Previously Untreated Adv Urothelial Carcinoma

Conference Coverage

Subgroup analyses of PFS and OS showed benefit with enfortumab vedotin-ejfv plus pembrolizumab vs platinum-based chemotherapy across all prespecified subgroups and the ITT population from the phase III EV-302/KEYNOTE-A39 trial in previously untreated locally advanced or metastatic urothelial cancer.

Released: February 01, 2024


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Exelixis, Inc., and Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.


Exelixis, Inc.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC